ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1819

Calcium Pyrophosphate Deposition Disease Is Associated with an Increased Prevalence of Nephrolithiasis

Alison Fernandes1, Yiran Jiang2, Katherine Sherman3, Ikechukwu Mbonu2, Rebecca Weiner2 and Ann Rosenthal2, 1Medical College of Wisconsin, Oconomowoc, WI, 2Medical College of Wisconsin, Milwaukee, WI, 3Zablocki VA Medical Center, Milwaukee, WI

Meeting: ACR Convergence 2022

Keywords: CPPD, Epidemiology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Calcium pyrophosphate deposition disease (CPDD) is a crystal arthropathy caused by calcium pyrophosphate (CPP) crystals. Individuals with CPDD also have increased risks for other manifestations of disordered mineralization, including osteoporosis and vascular calcification. To our knowledge, there are no prior studies investigating the potential association of CPDD and nephrolithiasis. Using data from the United States national Veterans Health Administration, we investigated this prevalence of nephrolithiasis in individuals with CPDD. Rates were compared with age and sex-matched controls. We also investigated the contribution of co-existing gout in patients with mixed crystal disease.

Methods: We performed a retrospective cohort analysis utilizing the Veterans Health Administration Corporate Data Warehouse, 2010 – 2014. CPDD was identified by ICD-9 code according to a previously validated rule, and nephrolithiasis and gout were also identified by ICD-9 codes. Each CPDD patient was age- and sex-matched to 4 controls. All subjects were required to have ≥2 encounters in the 365 days before and including the index date. Univariable analysis among CPDD, nephrolithiasis, and gout were performed using Chi Square.

Results: The study population was comprised of 110,796 individuals including 23,470 CPDD patients and 87,326 matched controls. The average age was 70.76 years, and 96.01% were male. More CPDD patients had nephrolithiasis (8.06% vs 4.88%; p< 0.0001) and gout (26.72% vs 9.15%; p< 0.0001) than controls. Nephrolithiasis rates were slightly higher when gout was present (6.89% vs 5.36%; p < 0.0001), but probably not to a level of clinical importance.

Conclusion: We show here that the prevalence of nephrolithiasis is positively associated with CPDD and was the presence of gout did not have a major impact on rates. Interestingly, the widely-distributed membrane protein known as ANKH, which is linked to familial CPDD, has recently been shown to transport factors important in nephrolithiasis, such as citrate. This observational study lends credence to the idea that abnormal mineralization occurs in multiple tissues in CPDD and the association with nephrolithiasis warrants further study.


Disclosures: A. Fernandes, None; Y. Jiang, None; K. Sherman, None; I. Mbonu, None; R. Weiner, None; A. Rosenthal, None.

To cite this abstract in AMA style:

Fernandes A, Jiang Y, Sherman K, Mbonu I, Weiner R, Rosenthal A. Calcium Pyrophosphate Deposition Disease Is Associated with an Increased Prevalence of Nephrolithiasis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/calcium-pyrophosphate-deposition-disease-is-associated-with-an-increased-prevalence-of-nephrolithiasis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/calcium-pyrophosphate-deposition-disease-is-associated-with-an-increased-prevalence-of-nephrolithiasis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology